fluticasone furoate/umeclidinium/vilanterol vs Glycopyrrolate/formoterol fumarate

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Chronic Obstructive Pulmonary Disease

Shared mechanisms: Muscarinic acetylcholine receptor (M3) · Beta-2 adrenergic receptor · full Chronic Obstructive Pulmonary Disease pipeline

fluticasone furoate/umeclidinium/vilanterol · Trelegy Ellipta

Marketed by GlaxoSmithKline

Approved in Chronic Obstructive Pulmonary Diseasesmall molecule combination
Reliable signal

NCT02164513 · Phase 3 · completed

This was a large randomized, double-blind, active-controlled trial in 10,355 COPD patients at 971 sites in 37 countries; the primary endpoint, annual on-treatment moderate/severe exacerbation rate, is a hard clinical outcome, and triple therapy significantly reduced exacerbations versus both dual-therapy comparators (rate ratio 0.75 vs UMEC/VI and 0.85 vs FF/VI, both p<0.001).

Next expected readout: September 2027 · NCT07192016 (registry estimate)

Reported efficacy

Annual Rate of On-treatment Moderate/Severe Exacerbations Comparing FF/UMEC/VI With UMEC/VI and FF/VI (Up to Week 52): Annual rate of on-treatment moderate/severe exacerbations: FF/UMEC/VI 0.91/yr vs FF/VI 1.07/yr (rate ratio 0.85, 95% CI 0.80-0.90, 15% reduction, p<0.001) vs UMEC/VI 1.21/yr (rate ratio 0.75, 95% CI 0.70-0.81, 25% reduction, p<0.001) (met)

Result source: NCT02164513

Glycopyrrolate/formoterol fumarate · Bevespi Aerosphere

Marketed by AstraZeneca

Approved in Chronic Obstructive Pulmonary Diseasesmall molecule combination
Weak signal

NCT03324607 · Phase 2/3 · completed

The study used a single treatment group without randomization, blinding, or a placebo or active comparator, and only 17 participants contributed to the primary imaging analysis. Its primary endpoints were surrogate MRI measures rather than established clinical outcomes, and the findings were mixed across those measures, so they provide limited evidence about Bevespi’s clinical effectiveness.

Reported efficacy

Ventilation Distribution as Measured by Ventilation Defect+Low Percent (Week 2); Barrier Uptake. (2 weeks); Red Blood Cell (RBC) Uptake (2 weeks): Ventilation Distribution as Measured by Ventilation Defect+Low Percent (Week 2): Treatment — Baseline: 57.8 percentage of total ventilation (Standard Deviation 8.4); Week 2: 52.5 percentage of total ventilation (Standard Deviation 10.6) (mixed)

Result source: NCT03324607

Results for Chronic Obstructive Pulmonary Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointfluticasone furoate/​umeclidinium/​vilanterolGlycopyrrolate/​formoterol fumarate
Moderate or severe exacerbations, annualised rate0.9 vs 1.1vs FF/VIwk 52 · n 4145NCT02164513
2 other results
  • 0.2 vs 0.3 100/62.5/25 µg · wk 24 · n 907 · Phase 3 · secondary NCT02345161
  • 0.2 vs 0.4 100/62.5/25 µg · wk 52 · n 210 · Phase 3 · secondary NCT02345161
—Not reported
Trough FEV1, change0.1 vs -0.0vs BUD/FOR100/62.5/25 µg · wk 24 · n 836NCT02345161
14 other results
  • 0.1 vs -0.1 100/62.5/25 µg · wk 52 · n 183 · Phase 3 · primary NCT02345161
  • 0.1 vs 0.1 100/62.5/25 · wk 24 · n 307 · Phase 3 · primary NCT02729051
  • 0.1 vs -0.0 wk 52 · n 3366 · Phase 3 · secondary NCT02164513
  • 0.1 vs 0.0 100/62.5/25 mcg · wk 12 · n 362 · Phase 4 · primary NCT03474081
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 12.14 · n 355 · Phase 4 · secondary NCT03478696
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 12.14 · n 358 · Phase 4 · secondary NCT03478683
  • 0.1 vs 0.0 100/62.5/25 mcg · wk 12 · n 376 · Phase 4 · secondary NCT03474081
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 12 · n 355 · Phase 4 · secondary NCT03478696
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 12 · n 358 · Phase 4 · secondary NCT03478683
  • 0.1 vs -0.0 100/62.5/25 mcg · wk 4 · n 385 · Phase 4 · secondary NCT03474081
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 4 · n 355 · Phase 4 · secondary NCT03478696
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 4 · n 358 · Phase 4 · secondary NCT03478683
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 0.29 · n 355 · Phase 4 · secondary NCT03478696
  • 0.0 vs 0.0 100/62.5/25 mcg · wk 0.29 · n 358 · Phase 4 · secondary NCT03478683
—Not reported
SGRQ total, change-6.6 vs -4.3vs BUD/FOR100/62.5/25 µg · wk 24 · n 846NCT02345161
3 other results
  • -4.6 vs -1.9 100/62.5/25 µg · wk 52 · n 182 · Phase 3 · primary NCT02345161
  • -5.5 vs -3.7 wk 52 · n 3318 · Phase 3 · secondary NCT02164513
  • -5.8 vs -4.9 100/62.5/25 · wk 24 · n 489 · Phase 3 · secondary NCT02729051
—Not reported
TDI focal score2.3 vs 1.7vs BUD/FOR100/62.5/25 µg · wk 24 · n 839NCT02345161
1 other result
  • 1.7 vs 1.4 100/62.5/25 µg · wk 52 · n 182 · Phase 3 · secondary NCT02345161
—Not reported

Moderate or severe exacerbations, annualised rate

fluticasone furoate/​umeclidinium/​vilanterol
0.9 vs 1.1vs FF/VIwk 52 · n 4145NCT02164513
2 other results
  • 0.2 vs 0.3 100/62.5/25 µg · wk 24 · n 907 · Phase 3 · secondary NCT02345161
  • 0.2 vs 0.4 100/62.5/25 µg · wk 52 · n 210 · Phase 3 · secondary NCT02345161
Glycopyrrolate/​formoterol fumarate
—Not reported

Trough FEV1, change

fluticasone furoate/​umeclidinium/​vilanterol
0.1 vs -0.0vs BUD/FOR100/62.5/25 µg · wk 24 · n 836NCT02345161
14 other results
  • 0.1 vs -0.1 100/62.5/25 µg · wk 52 · n 183 · Phase 3 · primary NCT02345161
  • 0.1 vs 0.1 100/62.5/25 · wk 24 · n 307 · Phase 3 · primary NCT02729051
  • 0.1 vs -0.0 wk 52 · n 3366 · Phase 3 · secondary NCT02164513
  • 0.1 vs 0.0 100/62.5/25 mcg · wk 12 · n 362 · Phase 4 · primary NCT03474081
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 12.14 · n 355 · Phase 4 · secondary NCT03478696
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 12.14 · n 358 · Phase 4 · secondary NCT03478683
  • 0.1 vs 0.0 100/62.5/25 mcg · wk 12 · n 376 · Phase 4 · secondary NCT03474081
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 12 · n 355 · Phase 4 · secondary NCT03478696
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 12 · n 358 · Phase 4 · secondary NCT03478683
  • 0.1 vs -0.0 100/62.5/25 mcg · wk 4 · n 385 · Phase 4 · secondary NCT03474081
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 4 · n 355 · Phase 4 · secondary NCT03478696
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 4 · n 358 · Phase 4 · secondary NCT03478683
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 0.29 · n 355 · Phase 4 · secondary NCT03478696
  • 0.0 vs 0.0 100/62.5/25 mcg · wk 0.29 · n 358 · Phase 4 · secondary NCT03478683
Glycopyrrolate/​formoterol fumarate
—Not reported

SGRQ total, change

fluticasone furoate/​umeclidinium/​vilanterol
-6.6 vs -4.3vs BUD/FOR100/62.5/25 µg · wk 24 · n 846NCT02345161
3 other results
  • -4.6 vs -1.9 100/62.5/25 µg · wk 52 · n 182 · Phase 3 · primary NCT02345161
  • -5.5 vs -3.7 wk 52 · n 3318 · Phase 3 · secondary NCT02164513
  • -5.8 vs -4.9 100/62.5/25 · wk 24 · n 489 · Phase 3 · secondary NCT02729051
Glycopyrrolate/​formoterol fumarate
—Not reported

TDI focal score

fluticasone furoate/​umeclidinium/​vilanterol
2.3 vs 1.7vs BUD/FOR100/62.5/25 µg · wk 24 · n 839NCT02345161
1 other result
  • 1.7 vs 1.4 100/62.5/25 µg · wk 52 · n 182 · Phase 3 · secondary NCT02345161
Glycopyrrolate/​formoterol fumarate
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety

Coverage. fluticasone furoate/umeclidinium/vilanterol: 5 of 5 rows · Glycopyrrolate/formoterol fumarate: 3 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricfluticasone furoate/​umeclidinium/​vilanterolGlycopyrrolate/​formoterol fumarate
FEV1
absolute change · L
No placebo or comparator arm
0.132 L @ 12wka,b,c,d
NCT05535972 · Phase 4 · registry result, not featured evidence
0.219 L @ 2wk*a,b,c,d
NCT03324607 · Phase 2/3 · combination · Chronic Obstructive Pulmonary Disease · phase 2/3 · converted to L from 219 mL as posted
Dropout rate
10.5%FF/UMEC/VIe
NCT02164513 · Phase 3
show 9 more results
—100/62.5/25
NCT02164513 · Phase 3
4.9%100/62.5/25 µg
NCT02345161 · Phase 3
6.1%
NCT04923347 · Phase 4 · registry result, not featured evidence
9.5%
NCT05535972 · Phase 4 · registry result, not featured evidence
3%100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI
NCT03467425 · Phase 4 · registry result, not featured evidence
4.3%100/62.5/25 mcg
NCT03474081 · Phase 4 · registry result, not featured evidence
4.6%100/62.5/25 mcg
NCT03478696 · Phase 4 · registry result, not featured evidence
3.6%100/62.5/25 mcg
NCT03478683 · Phase 4 · registry result, not featured evidence
5.7%100/62.5/25
NCT02729051 · Phase 3 · registry result, not featured evidence
0%f
NCT03324607 · Phase 2/3 · combination · Chronic Obstructive Pulmonary Disease · phase 2/3
show 1 more result
—
NCT03081156 · Phase 4 · registry result, not featured evidence
Discontinued due to AEs
3.9%FF/UMEC/VIe
NCT02164513 · Phase 3
show 9 more results
—100/62.5/25
NCT02164513 · Phase 3
1.8%100/62.5/25 µg
NCT02345161 · Phase 3
—
NCT04923347 · Phase 4 · registry result, not featured evidence
1.3%
NCT05535972 · Phase 4 · registry result, not featured evidence
0.6%100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI
NCT03467425 · Phase 4 · registry result, not featured evidence
1.5%100/62.5/25 mcg
NCT03474081 · Phase 4 · registry result, not featured evidence
0.3%100/62.5/25 mcg
NCT03478696 · Phase 4 · registry result, not featured evidence
1.4%100/62.5/25 mcg
NCT03478683 · Phase 4 · registry result, not featured evidence
4%100/62.5/25
NCT02729051 · Phase 3 · registry result, not featured evidence
—f
NCT03324607 · Phase 2/3 · combination · Chronic Obstructive Pulmonary Disease · phase 2/3
show 1 more result
—
NCT03081156 · Phase 4 · registry result, not featured evidence
Serious AEs
—FF/UMEC/VIe
NCT02164513 · Phase 3
show 9 more results
21.6%100/62.5/25
NCT02164513 · Phase 3
6.7%100/62.5/25 µg
NCT02345161 · Phase 3
0.4%
NCT04923347 · Phase 4 · registry result, not featured evidence
4.1%
NCT05535972 · Phase 4 · registry result, not featured evidence
7.4%100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI
NCT03467425 · Phase 4 · registry result, not featured evidence
3.3%100/62.5/25 mcg
NCT03474081 · Phase 4 · registry result, not featured evidence
4.4%100/62.5/25 mcg
NCT03478696 · Phase 4 · registry result, not featured evidence
8%100/62.5/25 mcg
NCT03478683 · Phase 4 · registry result, not featured evidence
10.4%100/62.5/25
NCT02729051 · Phase 3 · registry result, not featured evidence
0%f
NCT03324607 · Phase 2/3 · combination · Chronic Obstructive Pulmonary Disease · phase 2/3
show 1 more result
12.5%
NCT03081156 · Phase 4 · registry result, not featured evidence
Most frequent reported AEs
100/62.5/25e
viral upper respiratory tract infection 12.5%
upper respiratory tract infection 7.2%
headache 5.6%
NCT02164513 · Phase 3
show 8 more results
100/62.5/25 µg
nasopharyngitis 7.9%
headache 4.8%
NCT02345161 · Phase 3
pyrexia 4.4%
headache 3.9%
NCT04923347 · Phase 4 · registry result, not featured evidence
dysphonia 0.4%
abdominal discomfort 0.2%
abdominal pain upper 0.2%
NCT05535972 · Phase 4 · registry result, not featured evidence
100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI
dyspnoea 2.1%
NCT03467425 · Phase 4 · registry result, not featured evidence
100/62.5/25 mcg
headache 4.5%
nasopharyngitis 4%
NCT03474081 · Phase 4 · registry result, not featured evidence
100/62.5/25 mcg
headache 3.6%
nasopharyngitis 1.9%
NCT03478696 · Phase 4 · registry result, not featured evidence
100/62.5/25 mcg
nasopharyngitis 5%
NCT03478683 · Phase 4 · registry result, not featured evidence
100/62.5/25
viral upper respiratory tract infection 10.6%
headache 6.1%
upper respiratory tract infection 3.4%
NCT02729051 · Phase 3 · registry result, not featured evidence
—

Notes

  1. aTrial phases differ: Phase 4 versus Phase 2/3.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 12 weeks versus 2 weeks.
  5. ePopulation comparability has not been reviewed for these studies.
  6. fPopulation comparability has not been reviewed for 1 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

fluticasone furoate/umeclidinium/vilanterol

Moderate or Severe Exacerbation Rate Annualized 0.91 vs 1.07 FF/VI per year @ 52wk
event rate · per year
NCT02164513 · Phase 3
show 2 more results
0.22 vs 0.34 BUD/FOR per year @ 24wk100/62.5/25 µg
NCT02345161 · Phase 3
0.2 vs 0.36 BUD/FOR per year @ 52wk100/62.5/25 µg
NCT02345161 · Phase 3
FEV1 Trough 0.094 vs -0.003 FF/VI L @ 52wk
absolute change · L
NCT02164513 · Phase 3
show 14 more results
0.142 vs -0.029 BUD/FOR L @ 24wk100/62.5/25 µg
NCT02345161 · Phase 3
0.126 vs -0.053 BUD/FOR L @ 52wk100/62.5/25 µg
NCT02345161 · Phase 3
0.115 vs 0.02 Tiotropium L @ 12wk100/62.5/25 mcg
NCT03474081 · Phase 4 · registry result, not featured evidence
0.115 vs -0.007 Tiotropium L @ 4wk100/62.5/25 mcg
NCT03474081 · Phase 4 · registry result, not featured evidence
0.105 vs 0.018 Tiotropium L @ 12wk100/62.5/25 mcg
NCT03474081 · Phase 4 · registry result, not featured evidence
0.015 vs -0.01 Budesonide/Formoterol Plus Tiotropium L @ 0.29wk100/62.5/25 mcg
NCT03478696 · Phase 4 · registry result, not featured evidence
0.044 vs -0.019 Budesonide/Formoterol Plus Tiotropium L @ 4wk100/62.5/25 mcg
NCT03478696 · Phase 4 · registry result, not featured evidence
0.024 vs -0.03 Budesonide/Formoterol Plus Tiotropium L @ 12wk100/62.5/25 mcg
NCT03478696 · Phase 4 · registry result, not featured evidence
0.029 vs -0.022 Budesonide/Formoterol Plus Tiotropium L @ 12.14wk100/62.5/25 mcg
NCT03478696 · Phase 4 · registry result, not featured evidence
0.008 vs 0.018 Budesonide/Formoterol Plus Tiotropium L @ 0.29wk100/62.5/25 mcg
NCT03478683 · Phase 4 · registry result, not featured evidence
0.046 vs -0.015 Budesonide/Formoterol Plus Tiotropium L @ 4wk100/62.5/25 mcg
NCT03478683 · Phase 4 · registry result, not featured evidence
0.04 vs -0.018 Budesonide/Formoterol Plus Tiotropium L @ 12wk100/62.5/25 mcg
NCT03478683 · Phase 4 · registry result, not featured evidence
0.026 vs -0.012 Budesonide/Formoterol Plus Tiotropium L @ 12.14wk100/62.5/25 mcg
NCT03478683 · Phase 4 · registry result, not featured evidence
0.113 vs 0.095 FF/VI + UMEC L @ 24wk100/62.5/25
NCT02729051 · Phase 3 · registry result, not featured evidence
SGRQ Total -5.5 vs -3.7 FF/VI score @ 52wk
absolute change · score
NCT02164513 · Phase 3
show 3 more results
-6.6 vs -4.3 BUD/FOR score @ 24wk100/62.5/25 µg
NCT02345161 · Phase 3
-4.6 vs -1.9 BUD/FOR score @ 52wk100/62.5/25 µg
NCT02345161 · Phase 3
-5.841 vs -4.935 FF/VI + UMEC score @ 24wk100/62.5/25
NCT02729051 · Phase 3 · registry result, not featured evidence
Time to First Moderate or Severe Exacerbation NA vs NA FF/VI months @ 52wk
time to event · months
Median time to onset
NCT02164513 · Phase 3
show 1 more result
NA vs 8.31 UMEC/VI months @ 52wk
Median time to onset
NCT02164513 · Phase 3
TDI Focal 2.29 vs 1.72 BUD/FOR score @ 24wk100/62.5/25 µg
absolute change · score
NCT02345161 · Phase 3
show 1 more result
1.74 vs 1.39 BUD/FOR score @ 52wk100/62.5/25 µg
NCT02345161 · Phase 3
EXACT-RS -1.45 vs -0.5 BUD/FOR score @ 4wk100/62.5/25 µg
absolute change · score
NCT02345161 · Phase 3
show 17 more results
-2 vs -0.77 BUD/FOR score @ 8wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.23 vs -1.05 BUD/FOR score @ 12wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.42 vs -1.09 BUD/FOR score @ 16wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.43 vs -1.02 BUD/FOR score @ 20wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.31 vs -0.96 BUD/FOR score @ 24wk100/62.5/25 µg
NCT02345161 · Phase 3
-1.24 vs -0.72 BUD/FOR score @ 4wk100/62.5/25 µg
NCT02345161 · Phase 3
-1.97 vs -0.9 BUD/FOR score @ 8wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.18 vs -1.21 BUD/FOR score @ 12wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.53 vs -1.52 BUD/FOR score @ 16wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.64 vs -1.53 BUD/FOR score @ 20wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.63 vs -1.52 BUD/FOR score @ 24wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.48 vs -1.16 BUD/FOR score @ 28wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.33 vs -0.9 BUD/FOR score @ 32wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.12 vs -0.62 BUD/FOR score @ 36wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.34 vs -1.11 BUD/FOR score @ 40wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.3 vs -0.81 BUD/FOR score @ 44wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.17 vs -0.64 BUD/FOR score @ 48wk100/62.5/25 µg
NCT02345161 · Phase 3
EXACT-RS -2.03 vs -0.61 BUD/FOR score @ 52wk100/62.5/25 µg
absolute change · score
EXACT-RS Scores, Week 49-52, n=179, 171
NCT02345161 · Phase 3
FEV1 Trough 0.0542 L @ 4wk
absolute change · L
No placebo or comparator arm
CFB to Day 28
NCT04923347 · Phase 4 · registry result, not featured evidence
FEV1 Trough 0.0317 L @ 12wk
absolute change · L
No placebo or comparator arm
CFB to Day 85
NCT04923347 · Phase 4 · registry result, not featured evidence
CAT Total -6.8 score @ 12wk
absolute change · score
No placebo or comparator arm
NCT05535972 · Phase 4 · registry result, not featured evidence
show 1 more result
-4.4 score @ 4wk
NCT05535972 · Phase 4 · registry result, not featured evidence
mMRC Dyspnea Scale -0.5 score @ 12wk
absolute change · score
No placebo or comparator arm
NCT05535972 · Phase 4 · registry result, not featured evidence
show 1 more result
-0.5 score @ 12wk
NCT05535972 · Phase 4 · registry result, not featured evidence
CAT 86% (n=422) @ 12wk
responder rate · % of participants
No placebo or comparator arm
NCT05535972 · Phase 4 · registry result, not featured evidence

+ 7 further endpoints in the CSV export.

Glycopyrrolate/formoterol fumarate

FVC 0.342 L @ 2wk
absolute change · L
No placebo or comparator arm
NCT03324607 · Phase 2/3 · combination · Chronic Obstructive Pulmonary Disease · phase 2/3 · converted to L from 342 mL as posted
Six Minute Walk 16.2 m @ 2wk
absolute change · m
No placebo or comparator arm
NCT03324607 · Phase 2/3 · combination · Chronic Obstructive Pulmonary Disease · phase 2/3
SGRQ Total -1.2 score @ 2wk
absolute change · score
No placebo or comparator arm
NCT03324607 · Phase 2/3 · combination · Chronic Obstructive Pulmonary Disease · phase 2/3
RPD -0.75 score @ 2wk
absolute change · score
No placebo or comparator arm
NCT03324607 · Phase 2/3 · combination · Chronic Obstructive Pulmonary Disease · phase 2/3
Exercise Endurance Time Seconds 382.5 vs 328 placebo seconds
absolute value · seconds
NCT03081156 · Phase 4 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: fluticasone furoate/umeclidinium/vilanterol's landscape · Glycopyrrolate/formoterol fumarate's landscape